

Halaven

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-888-877-0518. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: ☐ Same as Rec	questing Provider
Name:	<u>.</u>
Fax:	Phone:
Rendering Provider Info: ☐ Same as Ref Name:	ferring Provider Same as Requesting Provider NPI#:
	Phone:
accepted compe	Phone: to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines.
Approvals may be subject t	Phone: to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines.
Approvals may be subject a accepted compe	Phone: to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kg
Approvals may be subject to accepted compete accepted compete Patient Weight: Patient Height:	Phone: to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kgcm
Approvals may be subject to accepted compete accepted compete Required Demographic Information: Patient Weight: Patient Height: Please indicate the place of service for the information and the place of service for the information accepted to the place of service for the information accepted to the place of service for the information accepted to the place of service for the information accepted to the place of service for the place of serv	Phone: to dosing limits in accordance with FDA-approved labeling, endia, and/or evidence-based practice guidelines. kgcm requested drug: ☐ Home ☐ Off Campus Outpatient Hospital

Criteria Questions:
1. What is the patient's diagnosis?
☐ Breast cancer, Continue to 2
☐ Liposarcoma, Continue to 2
☐ Pleomorphic rhabdomyosarcoma, <i>Continue to 2</i>
☐ Retroperitoneal/intra-abdominal soft tissue sarcoma, Continue to 2
☐ Extremity/body wall or head/neck soft tissue sarcoma, Continue to 2
☐ Other, please specify, Continue to 2
 2. Is this a request for continuation of therapy with the requested drug? ☐ Yes, Continue to 3 ☐ No, Continue to 4
3. Is there evidence of disease progression or unacceptable toxicity while on the current regimen? ☐ Yes, No Further Questions ☐ No, No Further Questions
4. What is the diagnosis?
☐ Breast cancer, <i>Continue to 5</i>
☐ Liposarcoma, Continue to 9
☐ Pleomorphic rhabdomyosarcoma, <i>Continue to 9</i>
☐ Retroperitoneal/intra-abdominal soft tissue sarcoma, <i>Continue to 9</i>
☐ Extremity/body wall or head/neck soft tissue sarcoma, <i>Continue to 9</i>
5. What is the clinical setting in which the requested drug will be used?
☐ Recurrent disease, Continue to 6
☐ Metastatic disease, <i>Continue to 6</i>
☐ No response to preoperative systemic therapy, <i>Continue to 6</i>
☐ Other, please specify, Continue to 6
6. What is the patient's human epidermal growth factor receptor 2 (HER2) status? <i>ACTION REQUIRED</i> : Attac chart note(s) or test results of human epidermal growth factor receptor 2 (HER2) testing results. ☐ HER2-positive <i>ACTION REQUIRED</i> : Submit supporting documentation, Continue to 7 ☐ HER2-negative <i>ACTION REQUIRED</i> : Submit supporting documentation, Continue to 8
☐ Unknown, No further questions
7. Will the requested drug be given in combination with trastuzumab (Herceptin) or margetuximab (Margenza)? Yes, No Further Questions No, No Further Questions
8. Will the requested drug be given as a single agent? Yes, No Further Questions No, No Further Questions

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Eribulin-Halaven SGM 1893-A – 6/2024.

CVS Caremark Specialty Pharmacy

• 2211 Sanders Road NBT-6

• Northbrook, IL 60062

Phone: 1-888-877-0518

• Fax: 1-855-330-1720

• www.caremark.com

9. Will the requested drug be given as single-agent therapy? ☐ Yes, No Further Questions	
□ No, No Further Questions	
I attest that this information is accurate and true, and that documen	ntation sunnarting this
information is available for review if requested by CVS Caremark of	r the benefit plan sponsor.
X	
X Prescriber or Authorized Signature	Date (mm/dd/yy)

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Eribulin-Halaven SGM 1893-A – 6/2024.